IMMP vs. AKBA, DSGN, EPIX, EBS, ALDX, PYXS, XBIT, OMER, TSVT, and GTHX
Should you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Akebia Therapeutics (AKBA), Design Therapeutics (DSGN), ESSA Pharma (EPIX), Emergent BioSolutions (EBS), Aldeyra Therapeutics (ALDX), Pyxis Oncology (PYXS), XBiotech (XBIT), Omeros (OMER), 2seventy bio (TSVT), and G1 Therapeutics (GTHX). These companies are all part of the "pharmaceutical preparations" industry.
Akebia Therapeutics (NASDAQ:AKBA) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, community ranking, risk and institutional ownership.
Akebia Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Immutep shares are owned by institutional investors. 3.8% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Immutep shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Immutep has lower revenue, but higher earnings than Akebia Therapeutics.
In the previous week, Immutep had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 4 mentions for Immutep and 3 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.53 beat Immutep's score of 0.36 indicating that Immutep is being referred to more favorably in the news media.
Akebia Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 334.78%. Immutep has a consensus price target of $8.50, indicating a potential upside of 187.16%. Given Immutep's higher possible upside, equities analysts clearly believe Akebia Therapeutics is more favorable than Immutep.
Immutep has a net margin of 0.00% compared to Immutep's net margin of -22.99%.
Akebia Therapeutics received 100 more outperform votes than Immutep when rated by MarketBeat users. However, 72.43% of users gave Immutep an outperform vote while only 63.96% of users gave Akebia Therapeutics an outperform vote.
Summary
Immutep beats Akebia Therapeutics on 8 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
